The collaboration combines Chinese hamster ovary cell line development with GMP media manufacturing to improve productivity and scalability in biologics production.
The teaming focuses on improving lentiviral and AAV delivery technologies to support more scalable and cost-effective cell and gene therapy manufacturing.
The Fishers campus expansion is expected to significantly increase sterile fill-finish output and support nearly 1,000 employees by the end of the decade.
The new financing supports the development of artificial intelligence models meant to enhance molecule design and expedite pathways to first-in-human studies.
The 700,000-square-foot, multi-site project is part of the company’s broader effort to expand domestic production capacity and strengthen U.S. pharmaceutical supply chains.
The agreement focuses on integrating ambient temperature biosample preservation with advanced 3D organoid models to support preclinical research and biotech developers.
The agreement reportedly will strengthen both companies’ sterile drug product manufacturing portfolios through the integration of fill-finish and packaging technologies.
The company opened a new site in India and expanded facilities in Korea and Singapore to support biologics, vaccine, and cell and gene therapy biomanufacturing.
John Murphy III, president and CEO of the Association for Accessible Medicines, unpacks what’s working, what’s not, and what must change for U.S. generic drug production.